Drug Profile
BAY 869596
Alternative Names: (d)-(18)F-fluoromethyltyrosine; (d)-18F-fluoromethyltyrosine; 18F DFMT; BAY-86-9596; d 18F FMT; D-18F- fluoromethyl tyrosine; D-18F-FMT; D-FMT; O-([18F]fluoromethyl)-D-tyrosineLatest Information Update: 01 Mar 2019
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammation; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(Diagnosis) in Netherlands (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(Diagnosis) in Singapore (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(Diagnosis) in Switzerland (IV, Injection)